Trevi Therapeutics Stock (NASDAQ:TRVI)
Previous Close
$5.56
52W Range
$2.30 - $7.39
50D Avg
$5.29
200D Avg
$3.73
Market Cap
$575.26M
Avg Vol (3M)
$2.15M
Beta
0.41
Div Yield
-
TRVI Company Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| CCCC | C4 Therapeutics, Inc. |
| CHRS | Coherus BioSciences, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| SEER | Seer, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| TARA | Protara Therapeutics, Inc. |
| ORIC | ORIC Pharmaceuticals, Inc. |
| BCAB | BioAtla, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| ANTX | AN2 Therapeutics, Inc. |